Serum level of brain-derived neurotrophic factor in Parkinson's disease: a meta-analysis.

Brain-derived neurotrophic factor (BDNF), a critical modulator in the neurodevelopment and maintenance of both central and peripheral nervous systems, is regarded as a potential therapeutic target of Parkinson's disease (PD). However, its association with PD remains unclear and the data are inconsistent. To explore the correlation, studies reporting BDNF levels in PD patients and healthy controls are searched and a sample of 1496 participants are pooled in the meta-analysis, demonstrating significantly decreased serum levels of BDNF in PD patients when compared with the healthy controls (SMD = -1.03; 95% CI [-1.83, -0.23]; P = .012). Meta-regression analysis indicates gender is an important confounding factor (Adj R = 69.20%, p = .004, I res = 90.64%), whereas age (Adj R = 11.91%, P = .95, I res = 96.86%), H-Y stages of PD progression (Adj R = -30.18%, P = .612, I res = 96.62%) and MoCA score assessed cognitive impairment (Adj R = 2.18%, P = .517, I res = 64.41%) show few moderating effects. The research provides evidence of moderate quality that blood levels of BDNF are decreased in PD patients despite various influencing factors, supporting an association between decreased level of peripheral BDNF and PD.